Change in attachment anxiety is associated with improved depression among women with binge eating disorder

About this resource

The study examined if the relationship between change in attachment insecurity and target symptom outcomes was moderated by treatment type. Women (N = 66) with binge eating disorder (BED) were randomly assigned to two treatment types: group cognitive-behavioral therapy (GCBT) or group psychodynamic-interpersonal psychotherapy (GPIP). Results indicated significant positive pre- to posttreatment changes in all attachment insecurity scales, but no difference between GCBT and GPIP on these changes. Change in attachment anxiety was related to improved depression for women completing GPIP, but not for women completing GCBT. This indicated a moderating effect of treatment type in explaining the relationship between change in attachment anxiety and improved depression. Changes in attachment anxiety may be important for symptom outcomes related to psychodynamic-interpersonal therapies.

AuthorTasca, Giorgio; Balfour, Louise; Ritchie, Kerri & Bissada, Hany
JournalPsychotherapy (Chicago, Ill.)

See also

Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: A randomized double-blind placebo-controlled comparison

Cognitive behavioral therapy (CBT) and certain medications have been shown to be effective for binge eating disorder (BED), but no controlled studies have compared psychological and pharmacological therapies.

Read more

Long-term stability of eating disorder diagnoses

OBJECTIVE: To estimate the familiality and heritability of binge eating disorder (BED).

Read more

Differentiating purging and nonpurging bulimia nervosa and binge eating disorder

To explore similarities and differences in clinical and personality variables across three groups: binge eating disorder (BED), bulimia nervosa-purging type (BN-P), and bulimia nervosa-non purging type (BN-NP).

Read more

Lisdexamfetamine dimesylate effects on binge eating behaviour and obsessive-compulsive and impulsive features in adults with binge eating disorder

In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced binge eating days (primary endpoint) in adults with binge eating disorder (BED).

Read more

Help us improve!

Give us feedback!

We will continue throughout 2019 to update and improve the NEDC website and welcome any feedback you may have on the site.

Provide feedback